Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01835223 · ClinicalTrials.gov registry record · Phase 1
Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT01835223 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 33 participants.
The verdict
NCT01835223, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and best dose of tivozanib and to see how well it works in treating patients with liver cancer that has spread to other parts of the body or cannot be removed by surgery. Tivozanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG Tivozanib (1mg)
- DRUG Tivozanib (1.5mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2013-07-11 |
| Est. Completion | 2019-11-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01835223
The ClinicalTrials.gov registry entry for NCT01835223 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tivozanib (1mg) is the first listed.
NCT01835223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01835223 about?
NCT01835223 is a clinical study titled "Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery". This phase I/II trial studies the side effects and best dose of tivozanib and to see how well it works in treating patients with liver cancer that has spread to other parts of the body or cannot be removed by surgery. Tivozanib may stop the growth of tumor cells by blocking some of the enzymes neede...
What is the current status of trial NCT01835223?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2013-07-11. Estimated completion is 2019-11-08.
What interventions are being tested in trial NCT01835223?
The interventions under investigation include: Tivozanib (1mg) (DRUG), Tivozanib (1.5mg) (DRUG).
Who is sponsoring clinical trial NCT01835223?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.